Cite
HARVARD Citation
Folkerts, K. et al. (2019). Cost-effectiveness of rivaroxaban versus apixaban for the initial treatment of venous thromboembolism and extended prevention of recurrences in the UK. Journal of medical economics. pp. 1179-1191. [Online].